...
search icon
imtx-img

Immatics NV, Common Stock

IMTX

NAQ

$5.85

-$0.29

(-4.72%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$722.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
589.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.82
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.3 L
$13.09 H
$5.85

About Immatics NV, Common Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMTXSectorS&P500
1-Week Return-1.85%-1.68%-0.63%
1-Month Return10.59%-0.67%0.46%
3-Month Return14.48%-9.11%6.48%
6-Month Return-13.08%-2.8%1.89%
1-Year Return-53.5%-8.53%8.94%
3-Year Return-27.33%8.87%58.67%
5-Year Return-58.36%33.75%91.64%
10-Year Return-39.06%75.55%181.75%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue31.25M34.76M172.83M54.00M155.84M[{"date":"2020-12-31","value":18.08,"profit":true},{"date":"2021-12-31","value":20.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.24,"profit":true},{"date":"2024-12-31","value":90.17,"profit":true}]
Cost of Revenue67.08M87.57M106.78M118.66M-[{"date":"2020-12-31","value":56.53,"profit":true},{"date":"2021-12-31","value":73.8,"profit":true},{"date":"2022-12-31","value":89.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(35.83M)(52.81M)66.05M(64.67M)155.84M[{"date":"2020-12-31","value":-22.99,"profit":false},{"date":"2021-12-31","value":-33.89,"profit":false},{"date":"2022-12-31","value":42.39,"profit":true},{"date":"2023-12-31","value":-41.5,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(114.65%)(151.92%)38.22%(119.76%)100.00%[{"date":"2020-12-31","value":-114.65,"profit":false},{"date":"2021-12-31","value":-151.92,"profit":false},{"date":"2022-12-31","value":38.22,"profit":true},{"date":"2023-12-31","value":-119.76,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses100.97M121.05M142.88M155.72M194.45M[{"date":"2020-12-31","value":51.92,"profit":true},{"date":"2021-12-31","value":62.25,"profit":true},{"date":"2022-12-31","value":73.48,"profit":true},{"date":"2023-12-31","value":80.08,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(69.72M)(86.29M)29.95M(101.72M)(38.62M)[{"date":"2020-12-31","value":-232.74,"profit":false},{"date":"2021-12-31","value":-288.09,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-339.6,"profit":false},{"date":"2024-12-31","value":-128.91,"profit":false}]
Total Non-Operating Income/Expense(141.56M)(3.09M)13.52M17.75M84.08M[{"date":"2020-12-31","value":-168.38,"profit":false},{"date":"2021-12-31","value":-3.68,"profit":false},{"date":"2022-12-31","value":16.08,"profit":true},{"date":"2023-12-31","value":21.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(229.62M)(93.33M)42.04M(96.99M)21.35M[{"date":"2020-12-31","value":-546.24,"profit":false},{"date":"2021-12-31","value":-222.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-230.74,"profit":false},{"date":"2024-12-31","value":50.78,"profit":true}]
Income Taxes(268.00K)1.73M4.55M(2.35M)6.13M[{"date":"2020-12-31","value":-4.37,"profit":false},{"date":"2021-12-31","value":28.17,"profit":true},{"date":"2022-12-31","value":74.28,"profit":true},{"date":"2023-12-31","value":-38.27,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(229.35M)(95.06M)37.48M(94.65M)15.22M[{"date":"2020-12-31","value":-611.86,"profit":false},{"date":"2021-12-31","value":-253.6,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-252.51,"profit":false},{"date":"2024-12-31","value":40.6,"profit":true}]
Income From Continuous Operations(229.62M)(93.33M)37.51M(96.99M)15.22M[{"date":"2020-12-31","value":-612.08,"profit":false},{"date":"2021-12-31","value":-248.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-258.55,"profit":false},{"date":"2024-12-31","value":40.57,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(229.35M)(95.06M)37.51M(96.99M)15.22M[{"date":"2020-12-31","value":-611.37,"profit":false},{"date":"2021-12-31","value":-253.4,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-258.55,"profit":false},{"date":"2024-12-31","value":40.57,"profit":true}]
EPS (Diluted)(21.55)(1.41)0.58(1.20)0.17[{"date":"2020-12-31","value":-3715.52,"profit":false},{"date":"2021-12-31","value":-243.1,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-206.9,"profit":false},{"date":"2024-12-31","value":29.07,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMTX
Current Ratio 10.28

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMTX
ROA (LTM) -5.84%
ROE (LTM) -4.78%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMTX
Debt Ratio Lower is generally better. Negative is bad. 0.16
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.84

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMTX
Trailing PE NM
Forward PE NM
P/S (TTM) 5.18
P/B 1.20
Price/FCF NM
EV/R 0.84
EV/Ebitda 7.19

FAQs

What is Immatics NV share price today?

Immatics NV (IMTX) share price today is $5.85

Can Indians buy Immatics NV shares?

Yes, Indians can buy shares of Immatics NV (IMTX) on Vested. To buy Immatics NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immatics NV be purchased?

Yes, you can purchase fractional shares of Immatics NV (IMTX) via the Vested app. You can start investing in Immatics NV (IMTX) with a minimum investment of $1.

How to invest in Immatics NV shares from India?

You can invest in shares of Immatics NV (IMTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immatics NV shares
What is Immatics NV 52-week high and low stock price?

The 52-week high price of Immatics NV (IMTX) is $13.09. The 52-week low price of Immatics NV (IMTX) is $3.3.

What is Immatics NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immatics NV (IMTX) is 1.20

What is the Market Cap of Immatics NV?

The market capitalization of Immatics NV (IMTX) is $722.01M

What is Immatics NV’s stock symbol?

The stock symbol (or ticker) of Immatics NV is IMTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top